# Julie Kanter

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 117 papers | 3,503 citations | 257450 24 h-index | 149698 56 g-index |
| 117 all docs | 117 docs citations | 117 times ranked | 2602 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 429-439. | 27.0 | 599 |
| 2 | A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519. | 27.0 | 401 |
| 3 | A Phase 3 Trial of<scp>l</scp>-Glutamine in Sickle Cell Disease. New England Journal of Medicine, 2018, 379, 226-235. | 27.0 | 378 |
| 4 | Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. New England Journal of Medicine, 2022, 386, 617-628. | 27.0 | 144 |
| 5 | Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematology,the, 2019, 6, e585-e596. | 4.6 | 128 |
| 6 | Management of sickle cell disease from childhood through adulthood. Blood Reviews, 2013, 27, 279-287. | 5.7 | 122 |
| 7 | A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine, 2016, 374, 625-635. | 27.0 | 117 |
| 8 | Density-based separation in multiphase systems provides a simple method to identify sickle cell disease. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14864-14869. | 7.1 | 107 |
| 9 | Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease. Blood Advances, 2020, 4, 2058-2063. | 5.2 | 93 |
| 10 | Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease. New England Journal of Medicine, 2022, 386, 138-147. | 27.0 | 86 |
| 11 | Validation of a novel point of care testing device for sickle cell disease. BMC Medicine, 2015, 13, 225. | 5.5 | 81 |
| 12 | Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. American Journal of Hematology, 2019, 94, 55-61. | 4.1 | 78 |
| 13 | A simple, rapid, low-cost diagnostic test for sickle cell disease. Lab on A Chip, 2013, 13, 1464. | 6.0 | 72 |
| 14 | Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances, 2020, 4, 3804-3813. | 5.2 | 57 |
| 15 | The sickle cell disease implementation consortium: Translating evidenceâ€based guidelines into practice for sickle cell disease. American Journal of Hematology, 2018, 93, E391-E395. | 4.1 | 52 |
| 16 | Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease. Blood, 2016, 128, 1176-1176. | 1.4 | 42 |
| 17 | Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4782-E4791. | 7.1 | 40 |
| 18 | American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. Blood Advances, 2021, 5, 3668-3689. | 5.2 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Validation of a Low-Cost Paper-Based Screening Test for Sickle Cell Anemia. PLoS ONE, 2016, 11, e0144901. | 2.5 | 33 |
| 20 | Ischemic stroke in children and young adults with sickle cell disease in the postâ€STOP era. American Journal of Hematology, 2019, 94, 1335-1343. | 4.1 | 33 |
| 21 | Increased prevalence of potential rightâ€toâ€left shunting in children with sickle cell anaemia and stroke. British Journal of Haematology, 2017, 176, 300-308. | 2.5 | 31 |
| 22 | Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care. JAMA Network Open, 2020, 3, e206016. | 5.9 | 30 |
| 23 | Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). Blood Advances, 2018, 2, 1969-1979. | 5.2 | 29 |
| 24 | Opioid utilization patterns in United States individuals with sickle cell disease. American Journal of Hematology, 2018, 93, E345-E347. | 4.1 | 29 |
| 25 | Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. Blood, 2020, 136, 623-626. | 1.4 | 26 |
| 26 | Barriers to Pediatric Sickle Cell Disease Guideline Recommendations. Global Pediatric Health, 2019, 6, 2333794X1984702. | 0.7 | 25 |
| 27 | Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. American Journal of Hematology, 2022, 97, 603-612. | 4.1 | 25 |
| 28 | Using Fludarabine to Reduce Exposure to Alkylating Agents in Children with Sickle Cell Disease Receiving Busulfan, Cyclophosphamide, and Antithymocyte Globulin Transplant Conditioning: Results of a Dose De-Escalation Trial. Biology of Blood and Marrow Transplantation, 2015, 21, 900-905. | 2.0 | 24 |
| 29 | Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513. | 7.4 | 24 |
| 30 | Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study. Blood, 2018, 132, 1026-1026. | 1.4 | 23 |
| 31 | Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke. Stroke, 2017, 48, 686-691. | 2.0 | 22 |
| 32 | The Genetic Landscape of Cerebral Steno-Occlusive Arteriopathy and Stroke in Sickle Cell Anemia. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2897-2904. | 1.6 | 22 |
| 33 | Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease. Therapeutic Advances in Hematology, 2020, 11, 204062072095500. | 2.5 | 22 |
| 34 | A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department. Annals of Emergency Medicine, 2020, 76, S64-S72. | 0.6 | 22 |
| 35 | Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multiâ€center <scp>HGB</scp>â€206 trial. American Journal of Hematology, 2020, 95, E239-E242. | 4.1 | 22 |
| 36 | Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry. Orphanet Journal of Rare Diseases, 2020, 15, 178. | 2.7 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Ticagrelor does not impact patientâ€reported pain in young adults with sickle cell disease: a multicentre, randomised phase <scp>II</scp>b study. British Journal of Haematology, 2019, 184, 269-278. | 2.5 | 20 |
| 38 | Transcranial Doppler Screening in a Current Cohort of Children With Sickle Cell Anemia: Results From the DISPLACE Study. Journal of Pediatric Hematology/Oncology, 2021, 43, e1062-e1068. | 0.6 | 20 |
| 39 | Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Advances, 2022, 6, 1243-1254. | 5.2 | 19 |
| 40 | Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA. BMJ Open, 2021, 11, e050880. | 1.9 | 18 |
| 41 | Gene therapy for sickle cell disease: where we are now?. Hematology American Society of Hematology Education Program, 2021, 2021, 174-180. | 2.5 | 18 |
| 42 | Transcranial doppler reâ€screening of subjects who participated in STOP and STOP II. American Journal of Hematology, 2016, 91, 1191-1194. | 4.1 | 17 |
| 43 | Improving Outcomes for Patients With Sickle Cell Disease in the United States. JAMA Health Forum, 2021, 2, e213467. | 2.2 | 17 |
| 44 | SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. Blood, 2016, 128, 1-1. | 1.4 | 16 |
| 45 | Successful Plerixafor-Mediated Mobilization, Apheresis, and Lentiviral Vector Transduction of Hematopoietic Stem Cells in Patients with Severe Sickle Cell Disease. Blood, 2017, 130, 990-990. | 1.4 | 16 |
| 46 | Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thrombosis and Haemostasis, 2017, 117, 580-588. | 3.4 | 14 |
| 47 | Novel findings from the multinational <scp>DOVE</scp> study on geographic and ageâ€related differences in pain perception and analgesic usage in children with sickle cell anaemia. British Journal of Haematology, 2019, 184, 1058-1061. | 2.5 | 13 |
| 48 | Perspectives of individuals with sickle cell disease on barriers to care. PLoS ONE, 2022, 17, e0265342. | 2.5 | 13 |
| 49 | <p>Development of a Severity Classification System for Sickle Cell Disease</p>. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 625-633. | 1.9 | 12 |
| 50 | Health-related Quality of Life in Children With Sickle Cell Disease Undergoing Chronic Red Cell Transfusion Therapy. Journal of Pediatric Hematology/Oncology, 2019, 41, 307-312. | 0.6 | 11 |
| 51 | Outcomes for Initial Patient Cohorts with up to 33 Months of Follow-up in the Hgb-206 Phase 1 Trial. Blood, 2018, 132, 1080-1080. | 1.4 | 11 |
| 52 | Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease. Blood, 2015, 126, 3233-3233. | 1.4 | 11 |
| 53 | Needs Assessment for Patients with Sickle Cell Disease in South Carolina, 2012. Public Health Reports, 2016, 131, 108-116. | 2.5 | 10 |
| 54 | Childhood Hearing Loss in Patients With Sickle Cell Disease in the United States. Journal of Pediatric Hematology/Oncology, 2019, 41, 124-128. | 0.6 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | High Healthcare Utilization in Adolescents with Sickle Cell Disease Prior to Transition to Adult Care: A Retrospective Study. Journal of Health Economics and Outcomes Research, 2019, 6, 174-184. | 1.2 | 10 |
| 56 | Feasibility of an mHealth self-management intervention for children and adolescents with sickle cell disease and their families. Translational Behavioral Medicine, 2021, 11, 724-732. | 2.4 | 7 |
| 57 | Exploring the Drivers of Potential Clinical Benefit in Initial Patients Treated in the Hgb-206 Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy. Blood, 2019, 134, 2061-2061. | 1.4 | 7 |
| 58 | The Relationships between Target Gene Transduction, Engraftment of HSCs and RBC Physiology in Sickle Cell Disease Gene Therapy. Blood, 2019, 134, 206-206. | 1.4 | 7 |
| 59 | Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemporary Clinical Trials, 2019, 85, 105835. | 1.8 | 6 |
| 60 | Practice patterns for stroke prevention using transcranial Doppler in sickle cell anemia: DISPLACE Consortium. Pediatric Blood and Cancer, 2020, 67, e28172. | 1.5 | 5 |
| 61 | Crizanlizumab 5.0 Mg/Kg Exhibits a Favorable Safety Profile in Patients with Sickle Cell Disease: Pooled Data from Two Phase II Studies. Blood, 2019, 134, 991-991. | 1.4 | 5 |
| 62 | Impact of TCD Screening Protocol on the Incidence of Hemorrhagic Stroke in Children and Young Adults with Sickle Cell Disease. Blood, 2015, 126, 3402-3402. | 1.4 | 5 |
| 63 | Ischemic Stroke in Children and Young Adults with Sickle Cell Disease (SCD) in the Post-STOP Era. Blood, 2015, 126, 68-68. | 1.4 | 5 |
| 64 | Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study. Blood, 2019, 134, 2289-2289. | 1.4 | 5 |
| 65 | Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD). Blood, 2021, 138, 12-12. | 1.4 | 5 |
| 66 | Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood, 0, , . | 1.4 | 5 |
| 67 | An approach to revising mHealth interventions for children and families: A case example in sickle cell disease. Research in Nursing and Health, 2019, 42, 483-493. | 1.6 | 4 |
| 68 | International Differences in Outpatient Pain Management: A Survey of Sickle Cell Disease. Journal of Clinical Medicine, 2019, 8, 2136. | 2.4 | 4 |
| 69 | Innovations in Targeted Antiâ€Adhesion Treatment for Sickle Cell Disease. Clinical Pharmacology and Therapeutics, 2020, 107, 140-146. | 4.7 | 4 |
| 70 | Kneeling Was the First Step for Sickle Cell Disease. Annals of Internal Medicine, 2021, 174, 1004-1005. | 3.9 | 4 |
| 71 | Gaps in the diagnosis and management of iron overload in sickle cell disease: a â€˜realâ€worldâ€™ report from the GRNDaD registry. British Journal of Haematology, 2021, 195, e157-e160. | 2.5 | 4 |
| 72 | Which adults with sickle cell disease need an evaluation for pulmonary embolism?. British Journal of Haematology, 2021, 195, 447-455. | 2.5 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Long-Term Outcome Following B-Cell Depletion Therapy with Rituximab In Children and Adults with Immune Thrombocytopenia (ITP). Blood, 2010, 116, 72-72. | 1.4 | 4 |
| 74 | A Simple, Rapid, Low-Cost Test for the Diagnosis of Sickle Cell Disease Using a Paper-Based Hemoglobin Solubility Assay. Blood, 2012, 120, 245-245. | 1.4 | 4 |
| 75 | GRNDaD: big data and sickle cell disease. Blood Advances, 2022, 6, 1088-1088. | 5.2 | 4 |
| 76 | Newborn Screening for Sickle Cell Disease in St. Vincent and the Grenadines: Results of a Pilot Newborn Screening Program. Global Pediatric Health, 2017, 4, 2333794X1773919. | 0.7 | 3 |
| 77 | Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease. Blood, 2018, 132, 505-505. | 1.4 | 3 |
| 78 | Definity, an affinity for painful crisis: a case series describing vaso-occlusive pain crises in sickle cell patients undergoing echocardiogram with Definity contrast. European Heart Journal - Case Reports, 2021, 5, ytaa555. | 0.6 | 3 |
| 79 | Practice patterns for neuroimaging and transfusion therapy for management of neurologic complications in sickle cell anemia: DISPLACE consortium. Pediatric Blood and Cancer, 2020, 67, e28569. | 1.5 | 2 |
| 80 | Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study. Blood, 2020, 136, 17-19. | 1.4 | 2 |
| 81 | Moyamoya Disease Predicts Progression of Cerebral Vasculopathy in Patients with Sickle Cell Disease Despite Chronic Transfusion Therapy. Blood, 2015, 126, 2071-2071. | 1.4 | 2 |
| 82 | Barriers to Implementation of Evidence-Based Stroke Prevention in Sickle Cell Disease: A Preliminary Study. Blood, 2015, 126, 749-749. | 1.4 | 2 |
| 83 | Regional- and Age-Related Differences in Pain in Children with Sickle Cell Anemia: Results from the Multinational DOVE Study. Blood, 2016, 128, 3654-3654. | 1.4 | 2 |
| 84 | Barriers and Facilitators to Transcranial Doppler Screening for Stroke Prevention in Children with Sickle Cell Anemia: Results from the Displace Consortium. Blood, 2019, 134, 3393-3393. | 1.4 | 2 |
| 85 | Multiâ€organ dysfunction secondary to abrupt discontinuation of voxelotor in a patient with severe sickle cell disease. American Journal of Hematology, 2022, 97, . | 4.1 | 2 |
| 86 | Incomplete implementation of guidelineâ€based stroke prevention therapy in sickle cell disease. American Journal of Hematology, 2018, 93, E222-E224. | 4.1 | 1 |
| 87 | Identified barriers and facilitators to stroke risk screening in children with sickle cell anemia: results from the DISPLACE consortium. Implementation Science Communications, 2021, 2, 87. | 2.2 | 1 |
| 88 | The Cambridge Automated Neuropsychological Testing Automated Battery (CANTAB) Is Feasible and Valuable for the Evaluation of Neurocognitive Deficits in Pediatric Patients with Sickle Cell Disease: Results of a Pilot Study. Blood, 2011, 118, 4839-4839. | 1.4 | 1 |
| 89 | Mind Over Matter: One Person's Journey From Patient to Change-Maker. , 2018, 15, . | | 1 |
| 90 | Established Prevention of Vaso-Occlusive Crises with Crizanlizumab Is Further Improved in Patients Who Follow the Standard Treatment Regimen: Post-Hoc Analysis of the Phase II Sustain Study. Blood, 2018, 132, 1082-1082. | 1.4 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Hydroxyurea Use and Outcomes of Pregnancy in Sickle Cell Disease. Blood, 2020, 136, 33-33. | 1.4 | 1 |
| 92 | Association Between Patent Foramen Ovale and Overt Ischemic Stroke in Children With Sickle Cell Disease. Frontiers in Neurology, 2021, 12, 761443. | 2.4 | 1 |
| 93 | Confirmation of the utility of the Wellsâ€™ Score for pulmonary embolism in patients with sickle cell disease. Journal of Thrombosis and Thrombolysis, 2022, , . | 2.1 | 1 |
| 94 | When Is the Optimal Time to Screen for Chlamydia in Adolescents and Young Adults With Sickle Cell Disease?. Clinical Pediatrics, 2015, 54, 149-151. | 0.8 | 0 |
| 95 | An unusual ultrasound appearance of renal hemosiderosis in acute sickle cell nephropathy. Radiology Case Reports, 2020, 15, 26-30. | 0.6 | 0 |
| 96 | Emergency department utilization for sickle cell disease in St. Vincent and the Grenadines. Pan African Medical Journal, 2021, 38, 100. | 0.8 | 0 |
| 97 | Adaptable stewardship during a pandemic: a multifaceted approach to sustaining the blood supply for individuals with sickle cell disease. International Journal of Laboratory Hematology, 2021, 43, O168-O170. | 1.3 | 0 |
| 98 | 48847 Assessing Transition Outcomes in Sickle Cell Disease (SCD) Prior To Implementation of A Formal Transition Program. Journal of Clinical and Translational Science, 2021, 5, 127-128. | 0.6 | 0 |
| 99 | One Small Step for Sickle Cell Disease: Many More to Go. Annals of Internal Medicine, 2021, 174, 1313-1314. | 3.9 | 0 |
| 100 | Annals On Call - Vascular Occlusive Crisis: Site of Care Matters. Annals of Internal Medicine, 2021, 174, OC1. | 3.9 | 0 |
| 101 | Vitamin D Deficiency In Pediatric Patients with Sickle Cell Disease Correlates with Reticulocytosis but Not with Clinical Disease Severity. Blood, 2010, 116, 4820-4820. | 1.4 | 0 |
| 102 | New Drugs to Match My New Genes? A Look Back at the 56th ASH Annual Meeting. , 2015, 12, . | | 0 |
| 103 | Novel Epigenetic Modulators That Promote Fetal Hemoglobin Production for the Prevention of Sickle Cell Disease Related Complications. Blood, 2015, 126, 973-973. | 1.4 | 0 |
| 104 | Evaluating Causes of Back Pain in Patients with Sickle Cell Disease. Blood, 2015, 126, 4593-4593. | 1.4 | 0 |
| 105 | Transfusion Practices Among Hematology/Oncology Healthcare Professionals. Blood, 2018, 132, 2552-2552. | 1.4 | 0 |
| 106 | Results from the Displace Consortium: Practice Patterns on the Use of Transcranial Doppler Screening for Risk of Stroke in Children with Sickle Cell Anemia. Blood, 2018, 132, 4697-4697. | 1.4 | 0 |
| 107 | Characteristics of Children with Abnormal TCD in the Modern Era: Results from the Displace Consortium. Blood, 2019, 134, 2270-2270. | 1.4 | 0 |
| 108 | Changes in Care Delivery for Children With Sickle Cell Anemia During the COVID-19 Pandemic. Journal of Pediatric Hematology/Oncology, 2021, 43, e1231-e1234. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood, 2020, 136, 22-24. | 1.4 | 0 |
| 110 | Predictors of Maternal Morbidity Among Participants Enrolled in the Sickle Cell Disease Implementation Consortium Registry. Blood, 2020, 136, 3-3. | 1.4 | 0 |
| 111 | Assessment of Impact of a mHealth Self-Management Intervention for Children with Sickle Cell Disease. Blood, 2020, 136, 11-12. | 1.4 | 0 |
| 112 | Evaluation of STOP Protocol Implementation for Abnormal TCD in Children with Sickle Cell Anemia at Risk for Stroke: Displace Consortium. Blood, 2020, 136, 22-23. | 1.4 | 0 |
| 113 | Sickle Stroke Screen: A Patient-Centered Educational Initiative for Children with Sickle Cell Anemia in the Displace Consortium. Blood, 2020, 136, 43-44. | 1.4 | 0 |
| 114 | Effect of Sickle Cell Related Therapies on Growth in Children with Sickle Cell Disease: Evidence from the Displace Study. Blood, 2020, 136, 21-21. | 1.4 | 0 |
| 115 | Sex Based Differences in Sickle Cell Disease. Blood, 2020, 136, 37-37. | 1.4 | 0 |
| 116 | Barriers and Facilitators to Chronic Red Cell Transfusion Therapy in Pediatric Sickle Cell Anemia. , 0, , 275275302110738. | | 0 |
| 117 | Genotype-phenotype and outcome associations in patients with Fanconi anemia: The National Cancer Institute cohort. Haematologica, 2022, , . | 3.5 | 0 |